{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:20Z","timestamp":1790983100185,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"abstract":"<jats:p>Pramipexole is a dopamine agonist used for the treatment of Parkinson\u2019s disease and restless leg syndrome. Amantadine is an antiviral agent with dopaminergic action that is approved for the treatment of motor symptoms associated with Parkinson\u2019s disease. This case report describes a patient with delusional parasitosis associated with concurrent use of pramipexole and amantadine. A 71-year-old man with a history of multiple sclerosis and Parkinson\u2019s disease presented with delusional parasitosis 4 months after his dose of pramipexole was increased from 0.75\u00a0mg\/day to 4.5\u00a0mg\/day. He was admitted to the geriatric psychiatric unit after his stool samples were found to be negative for parasites. A pharmacist evaluated his medications and noted that pramipexole and amantadine were independently associated with delusional parasitosis. Pramipexole and amantadine were subsequently discontinued, the patient was discharged and delusions completely resolved 4 months post-discontinuation. Concomitant use of pramipexole and amantadine may have led to delusional parasitosis. A literature review suggests that delusional parasitosis may be linked to striatal dopamine transporter dysfunction. In this case, the Naranjo Probability Score indicated that a drug-induced adverse event was \u201cprobable\u201d. The effects of these medications may have been enhanced by the patient\u2019s advanced age and the administration of pramipexole at the maximum recommended dose. Delusional parasitosis can occur in patients receiving concomitant treatment with pramipexole and amantadine. Patients receiving high doses of these agents in combination with other risk factors such as advanced age and impaired renal function should be monitored for symptoms of delusional parasitosis.<\/jats:p>","DOI":"10.1177\/08971900261486915","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:50:27Z","timestamp":1788501027000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ekbom\u2019s Delusional Parasitosis Related to Pramipexole and Amantadine Use: A Case Report"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-9235","authenticated-orcid":false,"given":"Helen C.","family":"Pervanas","sequence":"first","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences, Manchester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Daly","sequence":"additional","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences, Manchester"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000284934"},{"issue":"6","key":"e_1_3_6_3_2","first-page":"415","article-title":"Ekbom syndrome: a disease between dermatology and psychiatry","volume":"143","author":"Simonetti V","year":"2008","unstructured":"Simonetti V, Strippoli D, Pinciara B, Spreafico A, Motolese A. Ekbom syndrome: a disease between dermatology and psychiatry. G Ital Dermatol Venereol. 2008;143(6):415-419.","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.012"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0365-05962010000400018"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12352"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00324-3"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03810.x"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.183"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70284-z"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0101-81082007000100017"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042151"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318185e774"},{"key":"e_1_3_6_14_2","volume-title":"Nuplazid (Pimavanserin) Package Insert","year":"2023","unstructured":"Nuplazid (Pimavanserin) Package Insert. San Diego, CA: Acadia Pharmaceuticals Inc.; 2023. Revised 2025."},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2006.07.061"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.08.015"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285608100325"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00309-4"},{"key":"e_1_3_6_20_2","volume-title":"Sinemet (carbidopa-levodopa) Tablets Package Insert","year":"2026","unstructured":"Sinemet (carbidopa-levodopa) Tablets Package Insert. Jersey City, NJ: Organon LLC, a Subsidiary of Organon & Co; 2026."},{"key":"e_1_3_6_21_2","volume-title":"Granules Package Insert","author":"Nexium (esomeprazole) capsules","year":"2023","unstructured":"Nexium (esomeprazole) capsules. Granules Package Insert. Wilmington, DE: Astrazeneca; 2023."},{"key":"e_1_3_6_22_2","volume-title":"(Famotidine Tablet) Consumer Package Insert","author":"Pepcid AC","year":"2023","unstructured":"Pepcid AC. (Famotidine Tablet) Consumer Package Insert. New Brunswick, NJ: Johnson & Johnson Consumer Inc; 2023."},{"key":"e_1_3_6_23_2","volume-title":"(Oxybutynin chloride) Package Insert","author":"Ditropan XL","year":"2021","unstructured":"Ditropan XL. (Oxybutynin chloride) Package Insert. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2021."},{"key":"e_1_3_6_24_2","unstructured":"Mirapex (pramipexole) package insert. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2021."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900261486915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900261486915","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900261486915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:35:15Z","timestamp":1788665715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900261486915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":23,"alternative-id":["10.1177\/08971900261486915"],"URL":"https:\/\/doi.org\/10.1177\/08971900261486915","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"08971900261486915"}}